reports
NEURONES : Mise à disposition des informations relatives à l’Assemblée...
NEURONES : Mise à disposition des informations relatives à l’Assemblée Générale Mixte du 6 juin 2024 INFORMATION PRESSERubrique : Assemblée Générale Nanterre, le 14 mai 2024 MODALITES DE MISE A DISPOSITION OU DECONSULTATION DES INFORMATIONS RELATIVESA L’ASSEMBLEE GENERALE MIXTE DU 6 JUIN 2024 L’Assemblée Générale Mixte des actionnaires de NEURONES se tiendra le jeudi 6 juin 2024, à 12h00, au siège social, 205 avenue Georges Clemenceau – 92000 Nanterre. L’avis préalable, comportant l’ordre du jour et le texte des résolutions proposées par le Conseil d’Administration, a été publié a...
Rheinmetall AG: 1 director
A director at Rheinmetall AG bought 1,950 shares at 517.463EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
JDC Group AG: 1 director
A director at JDC Group AG bought 2,346 shares at 23.438EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Delårsrapport for Dantax A/S for perioden 1. juli 2023 - 31. marts 202...
Delårsrapport for Dantax A/S for perioden 1. juli 2023 - 31. marts 2024 Delårsrapport for Dantax A/S for perioden 1. juli 2023 - 31. marts 2024Resume:• Periodens resultat før skat blev et overskud på 11,9 mio. kr. og efter skat et overskud på 9,3 mio. kr., mod etoverskud på 7,3 mio. kr. før skat og 5,6 mio. kr. efter skat sidste år. Resultatet af primær drift udgør 1,2 mio.kr. før skat og 0,9 mio. kr. efter skat og resultatet af finansielle poster udgør 10,7 mio. kr. før skat og 8,4 mio.kr. efter skat.• En del af selskabets overskydende likviditet er investeret i børsnoterede aktier. I peri...
Absci Reports Business Updates and First Quarter 2024 Financial and Op...
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024. "During the first quarter, we made significant strides in advancing both our internal and partnered programs according to plan," said Sean McC...
Gain Therapeutics Reports Financial Results for First Quarter 2024 and...
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update. Corporate Highlights from Q1 2024 to Date Announced Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Tri...
Xilio Therapeutics Announces Pipeline and Business Updates and First Q...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 Advancing research-stage pipeline of tumor-activated bispecifics and immune cell engagers Anticipate cash runway into the second quarter of 2025 WALTHAM, Mass., May 14...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Z...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML – Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has completed enrollment of 85 patients in the Phase 2 portion of ...
Medigene AG Extends Cash Runway into July 2025 After Successful Oversu...
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 2024Use of proceeds from recent capital raise further advances plans for first patient enrollment in MDG1015 Phase 1 dose escalation trial by end of 2024, subject to additional financing Planegg/Martinsried, May 14, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology plat...
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Co...
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis 12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in cough severity reported in bexotegrast-treated patients at all timepoints compared to placebo Bexotegrast 160 mg was well tolerated over 12 weeks of treatment with no serious adverse events and no discontinuations ...
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring As...
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan – Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – – Validated in standalone and multi-reader, multi-case clinical studies conducted by world-renowned experts – – Urologists testing this TULSA-AI module improved their segmentation accuracy and were 32% faster in their contours – TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:P...
Alimera Sciences Reports First Quarter 2024 Results
Alimera Sciences Reports First Quarter 2024 Results Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to...
MiNK Reports First Quarter 2024 Results
MiNK Reports First Quarter 2024 Results Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS)AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to tr...
Pyxis Oncology Provides Corporate Update and Reports Financial Results...
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financi...
nCino Announces Timing of its First Quarter Fiscal Year 2025 Financial...
nCino Announces Timing of its First Quarter Fiscal Year 2025 Financial Results Conference Call WILMINGTON, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, will report financial results for its first quarter ended April 30, 2024, after the market close on Wednesday, May 29, 2024. nCino will host a conference call and webcast that day at 4:30 p.m. ET to discuss its financial results. Event: nCino’s First Quarter Fiscal Year 2025 Financial Results Conference CallDate and Time: Wednesday, May 29, 2024 at 4:30 p.m...
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio Welcomes clients and members to its best-in-class platform DRAPER, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity"), the leader in Health Savings Account (HSA) and consumer-directed benefits administration, is pleased to announce the completed transfer of Conduent’s (Nasdaq: CNDT) BenefitWallet HSA portfolio. HealthEquity Chief Executive Officer, Jon Kessler said, "We are thrilled to welcome BenefitWallet clients and members as partners on our mission to save and improve lives by em...
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch G...
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentatio...
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect ...
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executi...
Batteh Named Saia’s Chief Financial Officer
Batteh Named Saia’s Chief Financial Officer JOHNS CREEK, Ga., May 14, 2024 (GLOBE NEWSWIRE) -- Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, today announced that Matthew Batteh has been promoted to Executive Vice President and Chief Financial Officer and Secretary, effective immediately. In this position, he will lead Saia’s finance, pricing, accounting and treasury functions and will work with other key members of Saia’s management team to execute Saia’s long-term vision. “...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial R...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ET LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its first quarter 2024 fi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.